WASHINGTON - The pharmaceutical and biotechnology industries' heavy reliance on patents and aggressive enforcement of intellectual property (IP) are creating an environment of intimidation that prevents scientists from using tools vital to innovation, researchers from McGill and Duke universities contended Tuesday during a Capitol Hill briefing. (BioWorld Today) Read More
